CA2366723C - Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes - Google Patents

Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes Download PDF

Info

Publication number
CA2366723C
CA2366723C CA2366723A CA2366723A CA2366723C CA 2366723 C CA2366723 C CA 2366723C CA 2366723 A CA2366723 A CA 2366723A CA 2366723 A CA2366723 A CA 2366723A CA 2366723 C CA2366723 C CA 2366723C
Authority
CA
Canada
Prior art keywords
fatty acid
anticancer compound
conjugate
taxane
mtd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2366723A
Other languages
English (en)
Other versions
CA2366723A1 (fr
Inventor
Nigel L. Webb
Matthews O. Bradley
Forrest Anthony
Mark Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Regent Inc
Original Assignee
Luitpold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/265,307 external-priority patent/US7235583B1/en
Application filed by Luitpold Pharmaceuticals Inc filed Critical Luitpold Pharmaceuticals Inc
Publication of CA2366723A1 publication Critical patent/CA2366723A1/fr
Application granted granted Critical
Publication of CA2366723C publication Critical patent/CA2366723C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des conjugués d'acides gras et d'agents anticancéreux utilisés dans le traitement du cancer, ainsi que des compositions et des formulations renfermant ces conjugués. L'invention concerne également des méthodes d'utilisation desdits conjugués.
CA2366723A 1999-03-09 2000-03-09 Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes Expired - Fee Related CA2366723C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/265,307 US7235583B1 (en) 1999-03-09 1999-03-09 Fatty acid-anticancer conjugates and uses thereof
US18615200P 2000-03-01 2000-03-01
US09/265,307 2000-03-01
US60/186,152 2000-03-01
PCT/US2000/006160 WO2000053231A2 (fr) 1999-03-09 2000-03-09 Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes

Publications (2)

Publication Number Publication Date
CA2366723A1 CA2366723A1 (fr) 2000-09-14
CA2366723C true CA2366723C (fr) 2011-08-02

Family

ID=26881822

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2366723A Expired - Fee Related CA2366723C (fr) 1999-03-09 2000-03-09 Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes

Country Status (10)

Country Link
EP (1) EP1163011A2 (fr)
JP (1) JP2002538224A (fr)
KR (1) KR20020000147A (fr)
CN (1) CN1377282A (fr)
AU (1) AU3733300A (fr)
CA (1) CA2366723C (fr)
CZ (1) CZ20013123A3 (fr)
HK (1) HK1040486A1 (fr)
RU (1) RU2001127313A (fr)
WO (1) WO2000053231A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US8552054B2 (en) * 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
PT1509256E (pt) 2002-05-24 2009-10-15 Angiotech Int Ag Composições e métodos de revestimento de implantes médicos
CA2529125A1 (fr) 2003-06-19 2004-12-23 Yeda Research & Development Co. Ltd. Lipopeptides antimicrobiens et anticancereux
CA2544128A1 (fr) * 2003-10-30 2005-05-12 The Research Foundation Of State University Of New York Conjugues taxoide/acide gras et preparations les contenant
WO2006098241A1 (fr) * 2005-03-14 2006-09-21 Otsuka Pharmaceutical Factory, Inc. Composition pharmaceutique contenant un médicament à peine soluble dans l'eau
KR100753112B1 (ko) * 2007-02-26 2007-08-29 (주)고려다이나믹스 카드 발권 시스템
AU2013288738A1 (en) * 2012-07-10 2015-01-29 Baseclick Gmbh Anandamide-modified nucleic acid molecules
CN117088935A (zh) * 2022-05-20 2023-11-21 上海维洱生物医药科技有限公司 一种雷公藤甲素木蜡酸酯及其脂质体与制备方法
KR20230174082A (ko) * 2022-06-20 2023-12-27 (주) 바이오인프라생명과학 약물을 전달하기 위한 초음파 감응형 약물전달체를 생성하는 방법 및 이를 이용한 초음파 감응형 약물전달체
WO2024110843A1 (fr) 2022-11-21 2024-05-30 Segena Corporation S.A. Amélioration de l'activité immunomodulatrice d'oligonucléotides par modification de longue durée de dianophore : procédés et applications
CN116676355B (zh) * 2023-08-03 2023-10-24 成都第一制药有限公司 一种催化合成山莨菪碱的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925327A (ja) * 1982-07-31 1984-02-09 Hidematsu Hirai 抗腫瘍性複合体の製造方法
WO1993011668A1 (fr) * 1991-12-10 1993-06-24 Rush-Presbyterian-St. Luke's Medical Center Procedes et compositions destines a reduire la multiresistance aux medicaments
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
DK0914116T3 (da) * 1996-05-22 2000-11-20 Protarga Inc Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6136988A (en) * 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same

Also Published As

Publication number Publication date
KR20020000147A (ko) 2002-01-04
EP1163011A2 (fr) 2001-12-19
CN1377282A (zh) 2002-10-30
WO2000053231A3 (fr) 2001-10-04
CA2366723A1 (fr) 2000-09-14
RU2001127313A (ru) 2003-09-20
CZ20013123A3 (cs) 2002-03-13
WO2000053231A2 (fr) 2000-09-14
JP2002538224A (ja) 2002-11-12
AU3733300A (en) 2000-09-28
HK1040486A1 (zh) 2002-06-14

Similar Documents

Publication Publication Date Title
US7816398B2 (en) Fatty alcohol drug conjugates
US8552054B2 (en) Fatty amine drug conjugates
CA2366723C (fr) Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes
US6576636B2 (en) Method of treating a liver disorder with fatty acid-antiviral agent conjugates
AU725759B2 (en) DHA-pharmaceutical agent conjugates
JP5421340B2 (ja) 癌治療のためのアジア酸またはアジアチコサイドの使用。
AU720704B2 (en) Conjugates of cis-docosahexaenoic acid and paclitaxel
US20080125380A1 (en) Fatty acid-anticancer conjugates and uses thereof
WO1997044336A9 (fr) Conjugues d'acide cis-docosahexaenoique et de paclitaxel
WO2014199239A2 (fr) Méthodes se rapportant à l'utilisation du conditionnement ischémique à distance
CA2408562A1 (fr) Formulations d'acide dehydroascorbique et leurs utilisations
WO2000067802A1 (fr) Compositions d'acides gras -n-substituted indol-3-glyoxyl-amide et leur utilisation
WO2011028860A2 (fr) Composés et compositions pour le traitement du cancer
AU2008203341A1 (en) Fatty acid-anticancer conjugates and uses thereof
AU2005201503A1 (en) Fatty acid-anticancer conjugates and uses thereof
AU1632801A (en) DHA-pharmaceutical agent conjugates

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170309